Citations

Clear

6274 citation(s) found for "To, Andrew".

A noncoding single-nucleotide polymorphism at 8q24 drives IDH1 -mutant glioma formation
Yanchus, Connor , Drucker, Kristen , Kollmeyer, Thomas M. , Tsai, Ricky , Winick‐Ng, Warren , Liang, Minggao , Malik, Ahmad , Pawling, Judy , Lorenzo, Silvana B. De, Ali, Asma, Decker, Paul A. , Kosel, Matt, Panda, Arijit , Al‐Zahrani, Khalid N. , Jiang, Lingyan , Browning, Jared , Lowden, Christopher , Hernández, J. Javier , Gosio, Jessica , Loganathan, Sampath K. , Berman, Jacob M. , Trcka, Daniel , Michealraj, Kulandaimanuvel Antony , Fortin, Jérôme, Carson, Brittany B. , Hollingsworth, Ethan W. , Jacinto, Sandra , Mazrooei, Parisa, Zhou, Lily , Elia, Andrew , Lupien, Mathieu , Murphy, Daniel J. , Wang, Liguo , Abyzov, Alexej , Dennis, James W. , Maass, Philipp G. , Wrensch, Margaret , Mak, Tak W. , Visel, Axel , Wrana, Jeffrey L. , Zadeh, Gelareh , Eckel‐Passow, Jeanette E. , Attisano, Liliana , Pombo, Ana , Kvon, Evgeny Z. , Jenkins, Robert B. , Schramek, Daniel , Drucker, Kristen L , De Lorenzo, Silvana B, Kosel, Matt L, Browning, Jared W L , Lowden, Chris , Hernandez, J Javier , Ahmed, Musaddeque , Loganathan, Sampath Kumar , Berman, Jacob , Trcka, Daniel , Hollingsworth, Ethan W , Elia, Andrew , Lupien, Mathieu , He, Housheng Hansen , Wang, Liguo , Abyzov, Alexej , Dennis, James W , Maass, Philipp G , Wilson, Michael D , Wrensch, Margaret , Mak, Tak , Pennacchio, Len A , Dickel, Diane E , Visel, Axel , Wrana, Jeffrey , Dirks, Peter , Eckel-Passow, Jeanette E , Attisano, Liliana , Pombo, Ana , Ida, Cristiane M , Kvon, Evgeny Z , Jenkins, RB , Schramek, Daniel , Kollmeyer, Thomas , Murphy, Daniel J , Decker, Paul A. , Kosel, Matthew , Geuenich, Michael J. , Ahmed, Musaddeque , He, Housheng Hansen , Campbell, Kieran R. , Wilson, Michael D. , Lachance, Daniel Honore , Wiencke, John K. , Taylor, Michael D. , Ida, Cristiane M.

Mayo Clinic

Science | October 6, 2022 | Volume: 378 | Issue: 6615 | Pages: 68-78

10.1126/science.abj2890 | PMID 36201590 Get It

Establishing causal links between inherited polymorphisms and cancer risk is challenging. Here, we focus on the single-nucleotide polymorphism rs55705857, which confers a sixfold greater risk of isocitrate dehydrogenase ( IDH) –mutant low-grade glioma (LGG). We reveal that rs55705857 itself is the causal variant and is associated with molecular pathways that drive LGG. Mechanistically, we show that rs55705857 resides within a brain-specific enhancer, where the risk allele disrupts OCT2/4 binding, allowing increased interaction with the Myc promoter and increased Myc expression. Mutating the orthologous mouse rs55705857 locus accelerated tumor development in an Idh1 R132H -driven LGG mouse model from 472 to 172 days and increased penetrance from 30% to 75%. Our work reveals mechanisms of the heritable predisposition to lethal glioma in ~40% of LGG patients.
Endoscopic Ultrasound-Guided Gastrojejunostomy for Superior Mesenteric Artery Syndrome Secondary to Rapid Weight Loss
Mahmoud, Tala , Akiki, Karl, Law, Ryan , Law, Ryan J, Storm, Andrew C. , Akiki, Karl

Mayo Clinic

ACG Case Reports Journal | October 6, 2022 | Volume: 9 | Issue: 10 | Pages: e00868

10.14309/crj.0000000000000868 | PMID 36212239 Get It

ABSTRACT A 19-year-old man diagnosed with diffuse large B-cell lymphoma undergoing chemotherapy presented for recurrent emesis and weight loss. Imaging studies of the abdomen demonstrated features of superior mesenteric artery syndrome. The patient deferred conservative treatment options and was deemed not to be a surgical candidate. Endoscopic ultrasound-guided gastroenterostomy using a lumen-apposing metal stent was performed to bypass the obstruction. Subsequently, the patient's oral intake and weight significantly improved. The stent was removed 6 months after placement with resolution of superior mesenteric artery syndrome symptoms.
Guidelines for Sexual Health Care for Prostate Cancer Patients: Recommendations of an International Panel
Wittmann, Daniela , McCaughan, Eilís , Faraday, Martha M., Duby, Ashley , Matthew, Andrew, Incrocci, Luca , Nelson, Christian J. , Elliott, Stacy , McLeod, Deborah , Yap, Tet , Higano, Celestia S. , Capellari, Emily, Glodé, Michael, Howell, Doug, Bennett, Nelson , Trost, Landon , Ouma, P Odiyo, Wang, Run , Salter, Carolyn A. , Skolarus, Ted A. , McPhail, John, McPhail, S. Morton, Brandon, Jan, Northouse, Laurel , Paich, Kellie , Pollack, Craig Evan , Shifferd, Jen, Erickson, Kim, Mulhall, John P. , Nelson, Christian J , Mehta, Akanksha , Burnett, Arthur L. “Bud” , Koontz, Bridget F. , Bober, Sharon L. , Capogrosso, Paolo , Loeb, Stacy , Goltz, Heather Honoré , Kirby, Michael G. , McPhail, Susan, Shifferd, Jennifer

Mayo Clinic

The Journal of Sexual Medicine | October 1, 2022 | Volume: 19 | Issue: 11 | Pages: 1655-1669

10.1016/j.jsxm.2022.08.197 | PMID 36192299 Get It

AbstractBackgroundPatients with prostate cancer suffer significant sexual dysfunction after treatment which negatively affects them and their partners psychologically, and strain their relationships.AimWe convened an international panel with the aim of developing guidelines that will inform clinicians, patients and partners about the impact of prostate cancer therapies (PCT) on patients’ and partners’ sexual health, their relationships, and about biopsychosocial rehabilitation in prostate cancer (PC) survivorship.MethodsThe guidelines panel included international expert researchers and clinicians, and a guideline methodologist. A systematic review of the literature, using the Ovid MEDLINE, Scopus, CINAHL, PsychINFO, LGBT Life, and Embase databases was conducted (1995–2022) according to the Cochrane Handbook for Systematic Reviews of Interventions. Study selection was based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Each statement was assigned an evidence strength (A-C) and a recommendation level (strong, moderate, conditional) based on benefit/risk assessment, according to the nomenclature of the American Urological Association (AUA). Data synthesis included meta-analyses of studies deemed of sufficient quality (3), using A Measurement Tool to Assess Systematic Reviews (AMSTAR).OutcomesGuidelines for sexual health care for patients with prostate cancer were developed, based on available evidence and the expertise of the international panel.ResultsThe guidelines account for patients’ cultural, ethnic, and racial diversity. They attend to the unique needs of individuals with diverse sexual orientations and gender identities. The guidelines are based on literature review, a theoretical model of sexual recovery after PCT, and 6 principles that promote clinician-initiated discussion of realistic expectations of sexual outcomes and mitigation of sexual side-effects through biopsychosocial rehabilitation. Forty-seven statements address the psychosexual, relationship, and functional domains in addition to statements on lifestyle modification, assessment, provider education, and systemic challenges to providing sexual health care in PC survivorship.Clinical ImplicationsThe guidelines provide clinicians with a comprehensive approach to sexual health care for patients with prostate cancer.Strengths & LimitationsThe strength of the study is the comprehensive evaluation of existing evidence on sexual dysfunction and rehabilitation in prostate cancer that can, along with available expert knowledge, best undergird clinical practice. Limitation is the variation in the evidence supporting interventions and the lack of research on issues facing patients with prostate cancer in low and middle-income countries.ConclusionThe guidelines document the distressing sexual sequelae of PCT, provide evidence-based recommendations for sexual rehabilitation and outline areas for future research.
Oncologist perspectives on tumor boards: Virtual meetings and EHR integration.
Arafat, Waddah , Wagner, Andrew J. , Martin, Daniel B., Sugalski, Jessica , Heinrichs, Tricia , Racz, Jennifer M. , Heinrichs, Tricia , Fu, Paul C. , Osterman, Travis , Tevaarwerk, Amyé

Mayo Clinic

Journal of Clinical Oncology | September 30, 2022 | Volume: 40 | Issue: 28_suppl | Pages: 46-46

10.1200/jco.2022.40.28_suppl.046 Get It

46 Background: Tumor boards (TBs) are considered a key component for ensuring high quality cancer care. However, little is known about TB operational aspects that impact effectiveness. We aimed to understand how TBs leverage Electronic Health Record (EHR) functionalities and how pandemic-driven transitions from in-person TBs to virtual TBs impacted TB quality and effectiveness. Methods: The National Comprehensive Cancer Network (NCCN) Oncology EHR Advisory Group formed a Workgroup to assess the current state of TBs, obtain providers’ views on ideal TB state, and develop recommendations for improving TB quality and effectiveness. The Workgroup surveyed providers in various specialties at 31 NCCN Member Institutions in March 2022. Results: 846 providers from 27 institutions responded to the survey (n = 76 respondents were excluded from analysis because they reported not participating in TBs). Almost all (n = 764/767, 99%) indicated that one or more participants always or frequently attended TB meetings virtually. When comparing (newly established) virtual to (pre-pandemic) in-person TBs, 69% indicated increased attendance at virtual TBs. 65% reported no change in case volume, and 56% reported unchanged discussion quality while 19% reported increased discussion quality when comparing virtual to in-person TB meetings. In regards to EHR integration, several gaps between current and ideal state were noted. For instance, 40% always or frequently added patients to the TB roster via the EHR, but 57% reported this functionality to be very important or important for TBs. Additionally, 53% always or frequently document TB recommendations within the EHR, while 87% indicated EHR documentation of recommendations as very important or important. Respondents reported that barriers to documentation include resource constraints, concerns with patient access to documentation, legal and liability concerns, and poor EHR functionality. Conclusions: Overall, the majority of responding providers reported virtual TBs to be at least similar in quality to in-person TB meetings. A major gap identified by this study is the lack of documentation of TB recommendations in the EHR. Workflows and EHR functionalities could be improved to fully optimize the EHR for TB management and documentation.[Table: see text]
Renal Transplant Rejection and Tolerance
Schinstock, Carrie A. , Bentall, Andrew

Mayo Clinic

Nephrology Self-Assessment Program | September 29, 2022 | Volume: 21 | Issue: 3 | Pages: 199-210

10.1681/nsap.00302022 Get It

Systemic sclerosis associated interstitial lung disease: a conceptual framework for subclinical, clinical and progressive disease
Roofeh, David , Brown, Kevin M. , Kazerooni, Ella A. , Tashkin, Donald P. , Assassi, Shervin , Martínez, Fernando J. , Wells, Athol U. , Raghu, Ganesh , Denton, Christopher P. , Chung, Leland W.K. , Matteson, Eric L. , Pauling, John D , Seibold, James R. , Volkmann, Elizabeth R. , Walsh, Simon , White, Eric S. , Barratt, Shaney , Domsic, Robyn T. , Dellaripa, Paul F. , Rosas, Iván O. , Bhatt, Nitin, Hsu, Vivien , Kahaleh, Bashar , Garcha, Puneet , Khanna, Surabhi , Lin, Celia J. F., Mathai, Stephen C. , Doyle, Tracy J. , Steen, Virginia , Zoz, Donald F., Rodríguez‐Pintó, Ignasi , Lewandoski, Andrew, Belloli, Elizabeth A. , Lescoat, Alain , Nagaraja, Vivek , Ye, Wen , Huang, Suiyuan, Maher, Toby M. , Khanna, Dinesh , Tashkin, Donald , Martinez, Fernando , Chung, Lorinda , Hoffmann-Vold, Anna-Maria , Distler, Oliver , Johannson, Kerri A , Allanore, Yannick , Matteson, Eric L , Kawano-Dourado, Leticia , Pauling, John D , Seibold, James R , Volkmann, Elizabeth R , Oddis, Chester V , White, Eric S , Barratt, Shaney L , Bernstein, Elana J , Domsic, Robyn T , Dellaripa, Paul F , Conway, Richard , Rosas, Ivan , Hsu, Vivien , Ingegnoli, Francesca , Kahaleh, Bashar , Garcha, Puneet , Gupta, Nishant , Korsten, Peter , Strand, Vibeke , Steen, Virginia , Ovalles-Bonilla, Juan , Rodriguez-Pinto, Ignasi , Shenoy, Padmanabha D , Lescoat, Alain , Nagaraja, Vivek , Maher, Toby , Khanna, Dinesh , Assassi, Shervin , Mathai, Stephen C , Hoffmann‐Vold, Anna‐Maria , Distler, Oliver , Kawano-Dourado, Letícia , Oddis, Chester V. , Bernstein, Elana J. , Conway, Richard , Ingegnoli, Francesca , Gupta, Nishant , Korsten, Peter , Lewandoski, Andrew

Mayo Clinic

Rheumatology | September 29, 2022 | Volume: 62 | Issue: 5 | Pages: 1877-1886

10.1093/rheumatology/keac557 | PMID 36173318 Get It

Abstract Objectives To establish a framework by which experts define disease subsets in systemic sclerosis associated interstitial lung disease (SSc-ILD). Methods A conceptual framework for subclinical, clinical and progressive ILD was provided to 83 experts, asking them to use the framework and classify actual SSc-ILD patients. Each patient profile was designed to be classified by at least four experts in terms of severity and risk of progression at baseline; progression was based on 1-year follow-up data. A consensus was reached if ≥75% of experts agreed. Experts provided information on which items were important in determining classification. Results Forty-four experts (53%) completed the survey. Consensus was achieved on the dimensions of severity (75%, 60 of 80 profiles), risk of progression (71%, 57 of 80 profiles) and progressive ILD (60%, 24 of 40 profiles). For profiles achieving consensus, most were classified as clinical ILD (92%), low risk (54%) and stable (71%). Severity and disease progression overlapped in terms of framework items that were most influential in classifying patients (forced vital capacity, extent of lung involvement on high resolution chest CT [HRCT]); risk of progression was influenced primarily by disease duration. Conclusions Using our proposed conceptual framework, international experts were able to achieve a consensus on classifying SSc-ILD patients along the dimensions of disease severity, risk of progression and progression over time. Experts rely on similar items when classifying disease severity and progression: a combination of spirometry and gas exchange and quantitative HRCT.
Increasing tissue requirements in lymphoma trials may exclude patients with high-risk disease or worse prognosis
Desai, Sanjal H. , Mwangi, Raphael , Ng, Wern Lynn , King, Rebecca L. , Maurer, Matthew J. , Cerhan, James R. , Feldman, Andrew L. , Farooq, Umar , Mou, Eric , Thompson, Carrie A. , Nowakowski, Grzegorz S. , Wang, Yucai , Witzig, T.E. , Feldman, Andrew L , Maurer, Matthew , Cerhan, James R , Farooq, Umar , Desai, Sanjal , Mou, Eric , Habermann, Thomas M. , Wang, Yucai , Witzig, Thomas E.

Mayo Clinic

Blood Advances | September 28, 2022 | Volume: 6 | Issue: 24 | Pages: 6180-6186

10.1182/bloodadvances.2022007569 | PMID 36170803 Get It

Abstract An enhanced understanding of the molecular heterogeneity of diffuse large B-cell lymphoma (DLBCL) has opened the door to clinical trials evaluating novel agents with subtype-specific activity. It is an emerging question whether core needle biopsies (CNB) can adequately meet the increasing tissue requirements of these clinical trials. This can potentially lead to selective enrollment of patients who can undergo excisional biopsy (EB). It is also important to know whether patients who can undergo extensive diagnostic work up differ in their disease characteristics and outcomes from those who cannot. In this observational study, we describe the characteristics, outcomes, and adequacy of diagnostic tissue in patients with newly diagnosed DLBCL and primary mediastinal large B-cell lymphoma who underwent EB vs CNB. Of the 1061 patients, 532 (49.8%) underwent EB and 529 (50.1%) underwent CNB. A significantly higher proportion of patients with CNB had advanced stage disease, an international prognostic index of ≥3, and inadequate tissue for molecular analyses. Patients with CNB had significantly worse 5-year event-free survival (67.6% vs 56.9%; hazard ratio [HR], 0.76; confidence interval [CI]95, 0.6-0.9, P < .001) and 5-year overall survival (76.4% vs 69.2%; HR, 0.8; CI95, 0.6-0.9, P < .001). Thus, patients who underwent CNB have poor-risk features and inferior outcomes on frontline chemoimmunotherapy, are more likely to have inadequate tissue for molecular analyses, and might not meet the tissue requirements of biomarker-driven clinical trials. Thus, the increasing tissue requirements of biomarker-driven clinical trials may result in the exclusion of patients with high-risk DLBCL who need novel agents.
The accuracy of ten common resting metabolic rate prediction equations in men and women collegiate athletes
Fields, Jennifer B. , Magee, Meghan K., Jones, Margaret T. , Askow, Andrew T. , Camic, Clayton L., Luedke, Joel, Jagim, Andrew R , Askow, Andrew T , Jagim, Andrew R.

Mayo Clinic

European Journal of Sport Science | September 28, 2022 | Volume: 23 | Issue: 10 | Pages: 1973-1982

10.1080/17461391.2022.2130098 | PMID 36168819 Get It

ABSTRACTPredictive resting metabolic rate (RMR) equations are widely used to determine total daily energy expenditure (TDEE). However, it remains unclear whether these predictive RMR equations accurately predict TDEE in the athletic populations. The purpose of this study was to examine the accuracy of 10 commonly used RMR prediction equations (Cunningham, De Lorenzo, Freire, Harris‐Benedict, Mifflin St. Jeor, Nelson, Owen, Tinsley, Watson, Schofield) in collegiate men and women athletes. One‐hundred eighty‐seven National Collegiate Athletic Association Division III men (n = 97) and women (n = 90) athletes were recruited to participate in one day of metabolic testing. RMR was measured using indirect calorimetry and body composition was analyzed using air displacement plethysmography. A repeated measures ANOVA with Bonferroni post hoc analyses was selected to determine mean differences between measured and predicted RMR. Linear regression analysis was used to assess the accuracy of each RMR prediction method (p<0.05). All prediction equations significantly underestimated RMR (p<0.001), although there was no difference between the De Lorenzo and Watson equations and measured RMR (p = 1.00) for women, only. In men, the Tinsley and Freire equations were the most agreeable formulas with the lowest root‐mean‐square prediction error value of 404 and 412 kcals, respectively. In women, the De Lorenzo and Watson equations were the most agreeable equations with the lowest root‐mean‐squared error value of 171 and 211 kcals, respectively. The results demonstrate that such RMR equations may underestimate actual energy requirements of athletes and thus, practitioners should interpret such values with caution.
Acute symptomatic seizures secondary to myelin oligodendrocyte glycoprotein antibody‐associated disease
Montalvo, Mayra , Khattak, Jamal F., Redenbaugh, Vyanka , Sánchez, Cristina Valencia, Datta, Abhigyan , Tillema, Jan‐Mendelt , Chen, John , Pittock, Sean J. , Dubey, Divyanshu , Chen, John J. , Britton, Jeffrey, Dubey, Divyanshu , Pittock, S J , Chen, John J , Datta, Abhigyan , Khattak, Jamal, Britton, Jeffrey W. , McKeon, Andrew , Flanagan, Eoin P.

Mayo Clinic

Epilepsia | September 28, 2022 | Volume: 63 | Issue: 12 | Pages: 3180-3191

10.1111/epi.17424 | PMID 36168809 Get It

Abstract Objective To report the clinical presentations and outcomes of patients with seizure and myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD). Methods We retrospectively reviewed the electronic medical records for clinical and paraclinical features among patients with seizures and MOG‐IgG (immunoglobulin G) seropositivity. Results We identified 213 patients with MOG‐IgG seropositivity who fulfilled criteria for MOGAD. Seizures attributed to central nervous system (CNS) autoimmunity were observed in 10% of patients ( n = 23: 19 children, 4 adults). The majority ( n = 19, 83%) had pediatric disease onset. Focal motor seizures were the most common seizure semiology (16/23; 70%). Focal to bilateral tonic‐clonic seizures were present in 12 patients (53%), and 3 patients (13%) developed status epilepticus. All patients had features of encephalitis at onset of seizures. Cerebral cortical encephalitis (CCE) was the most common radiological finding (10 unilateral and 5 bilateral cases). Eight of 23 patients (35%) had only CCE, six of 23 patients (26%) had only acute disseminated encephalomyelitis (ADEM), and seven of 23 patients (30%) had features of both. Fifteen patients (65%) had leptomeningeal enhancement. Three patients (13%) had coexistence of N ‐methyl‐ d ‐aspartate receptor (NMDAR) IgG. Only 3 of 23 patients (13%) developed drug‐ resistant epilepsy. Although the majority had MOGAD relapses (14/23, 60%) had only 5 of 23 patients had recurrence of episodes of encephalitis with associated seizures. Twenty‐one of 23 patients (91%) had seizure freedom at last follow‐up. Significance MOG‐IgG evaluation should be considered in patients who present with encephalitis and focal motor and/or focal to bilateral tonic‐clonic seizures, especially pediatric patients with magnetic resonance imaging (MRI) brain findings consistent with CCE, ADEM, or other MOGAD presentations. The majority of these seizures are self‐limited and do not require maintenance/chronic antiseizure medications. Although seizure recurrence is uncommon, many patients have MOGAD relapses in the form of encephalitis and optic neuritis.
Cochlear Implantation After Intralabyrinthine Schwannoma Microsurgical Resection
Goates, Andrew J. , Nassiri, Ashley M. , Carlson, Matthew L. , Gompel, Jamie J. Van

Mayo Clinic

Otology & Neurotology | September 27, 2022 | Volume: 44 | Issue: 1 | Pages: e51-e52

10.1097/mao.0000000000003705 | PMID 36167026 Get It

Abstract Cochlear implantation after microsurgical resection of intralabyrinthine schwannomas has shown promising results in a limited number of small studies with safe and favorable outcomes. Cochlear implantation is a mainstream treatment for advanced bilateral sensorineural hearing loss and, more recently, has been applied to patients with single-sided deafness. The case presented is a 66-year-old gentleman with a history of progressive right-sided sensorineural hearing loss and bothersome tinnitus with a right intralabyrinthine schwannoma involving the semicircular canals, vestibule, and basal turn of the cochlea. The authors describe concomitant cochlear implantation after microsurgical resection of an intralabyrinthine schwannoma. Intralabyrinthine schwannomas represent an uncommon subtype of benign tumors arising from the terminal branches of the vestibulocochlear nerve. Symptoms often include sensorineural hearing loss, dizziness, and tinnitus, and in this location, symptoms often arise at a small tumor size. In this featured case, we present a patient who underwent gross total tumor resection and cochlear implantation for hearing rehabilitation and treatment of tinnitus. Six months after surgery, the patient achieved good device performance, scoring 46% on consonant–nucleus–consonant word testing and 66% on AzBio sentence testing, and subjective improvement in his tinnitus.